Lee's Pharmaceutical Holdings Limited (Lee's Pharm or “the Group”) is a public biopharmaceutical company with a long history of operations in China's pharmaceutical industry. It is a fully integrated company with the necessary infrastructure in drug development, clinical trials, regulations, manufacturing, sales, and marketing in China with a global outlook. Currently, they have 14 products in the PRC. Their focus is on cardiovascular and infectious diseases, dermatology, oncology, gynecology, ophthalmology, and other areas. They have more than 30 products in various stages of development, both from their own R&D practices and from the recently acquired licensing and distribution rights from companies based in the US, Europe, and Japan. In 2010, Lee's Pharm was named the Best Small-Cap Company in China (2nd Rank) by Finance Asia. In September 2011, Forbes included them in its list of Asia's 200 Best Under A Billion Company (with turnover of less than US$1 billion). The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia, providing innovative products to fight illnesses and improve the health and quality of life of people.